These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 32929540)
1. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Kizub DA; Miao J; Schubert MM; Paterson AHG; Clemons M; Dees EC; Ingle JN; Falkson CI; Barlow WE; Hortobagyi GN; Gralow JR Support Care Cancer; 2021 May; 29(5):2509-2517. PubMed ID: 32929540 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer. Rugani P; Luschin G; Jakse N; Kirnbauer B; Lang U; Acham S Clin Oral Investig; 2014; 18(2):401-7. PubMed ID: 23749244 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. Kuroshima S; Sasaki M; Nakajima K; Tamaki S; Hayano H; Sawase T Bone; 2018 Jul; 112():177-186. PubMed ID: 29729428 [TBL] [Abstract][Full Text] [Related]
4. Clinical profile of individuals with bisphosphonate-related osteonecrosis of the jaw: an integrative review. Maciel AP; Quispe RA; Martins LJO; Caldas RJ; Santos PSDS Sao Paulo Med J; 2020; 138(4):326-335. PubMed ID: 32725058 [TBL] [Abstract][Full Text] [Related]
5. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404 [TBL] [Abstract][Full Text] [Related]
6. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years. Mücke T; Deppe H; Hein J; Wolff KD; Mitchell DA; Kesting MR; Retz M; Gschwend JE; Thalgott M J Craniomaxillofac Surg; 2016 Oct; 44(10):1689-1693. PubMed ID: 27555374 [TBL] [Abstract][Full Text] [Related]
7. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. Assael LA J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813 [TBL] [Abstract][Full Text] [Related]
8. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129 [TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. O'Ryan FS; Lo JC J Oral Maxillofac Surg; 2012 Aug; 70(8):1844-53. PubMed ID: 22595135 [TBL] [Abstract][Full Text] [Related]
10. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database. Amigues C; Fresse A; Roux CH; Gauthier S; Vieillard MH; Drici MD; Breuil V; Joint Bone Spine; 2023 Dec; 90(6):105599. PubMed ID: 37271278 [TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases. Di Fede O; Fusco V; Matranga D; Solazzo L; Gabriele M; Gaeta GM; Favia G; Sprini D; Peluso F; Colella G; Vescovi P; Campisi G Eur J Intern Med; 2013 Dec; 24(8):784-90. PubMed ID: 23768563 [TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate related osteonecrosis of the jaws: spontaneous or dental origin? Pichardo SE; van Merkesteyn JP Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Sep; 116(3):287-92. PubMed ID: 23953415 [TBL] [Abstract][Full Text] [Related]
13. Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model. Ersan N; van Ruijven LJ; Bronckers AL; Olgaç V; Ilgüy D; Everts V Dentomaxillofac Radiol; 2014; 43(1):20130144. PubMed ID: 24170800 [TBL] [Abstract][Full Text] [Related]
14. [Bisphosphonate-related osteonecrosis of the jaw-after a decade has passed]. Yoneda T Clin Calcium; 2014 Mar; 24(3):407-15. PubMed ID: 24576938 [TBL] [Abstract][Full Text] [Related]
15. [Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates]. Endo Y; Funayama H; Yamaguchi K; Monma Y; Yu Z; Deng X; Oizumi T; Shikama Y; Tanaka Y; Okada S; Kim S; Kiyama T; Bando K; Shima K; Suzuki H; Takahashi T Yakugaku Zasshi; 2020; 140(1):63-79. PubMed ID: 31902887 [TBL] [Abstract][Full Text] [Related]
16. Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat. Kün-Darbois JD; Libouban H; Mabilleau G; Pascaretti-Grizon F; Chappard D Clin Oral Investig; 2018 Dec; 22(9):2997-3006. PubMed ID: 29453497 [TBL] [Abstract][Full Text] [Related]
17. Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series. López-Cedrún JL; Sanromán JF; García A; Peñarrocha M; Feijoo JF; Limeres J; Diz P Br J Oral Maxillofac Surg; 2013 Dec; 51(8):874-9. PubMed ID: 23866309 [TBL] [Abstract][Full Text] [Related]
18. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Assaf AT; Smeets R; Riecke B; Weise E; Gröbe A; Blessmann M; Steiner T; Wikner J; Friedrich RE; Heiland M; Hoelzle F; Gerhards F Anticancer Res; 2013 Sep; 33(9):3917-24. PubMed ID: 24023329 [TBL] [Abstract][Full Text] [Related]
19. A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery? O'Connell JE; Ikeagwani O; Kearns GJ Ir J Med Sci; 2012 Jun; 181(2):237-42. PubMed ID: 22223192 [TBL] [Abstract][Full Text] [Related]
20. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis. Nisi M; La Ferla F; Karapetsa D; Gennai S; Miccoli M; Baggiani A; Graziani F; Gabriele M Int J Oral Maxillofac Surg; 2015 May; 44(5):586-91. PubMed ID: 25701305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]